Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 vs Camrelizumab in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT05576272Phase 3Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab, tuvonralimab in nasopharyngeal carcinoma (NPC), sponsored by Qilu Pharmaceutical. Started May 2022; status: active, not recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05576272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576272.